| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2013-11-14 | vaccine for the H7N9 avian influenza virus | H7N9 avian influenza virus |
1 | Novartis (Switzerland) | Infectious diseases |
| 2013-11-14 | remimazolam (ONO-2745) | sedation general anaesthesia |
2-3 | Paion (Germany) Ono Pharmaceutical (Japan) | CNS diseases |
| 2013-11-13 | combination of insulin Glargine (Lantus®, Sanofi) with a fast-acting insulin analog, insulin Lispro (Humalog®, Eli Lilly) | type 1 diabetes |
1-2 | Adocia (France) | Metabolic diseases |
| 2013-11-12 | defibrotide | prevention and treatment of hepatic veno-occlusive disease (VOD) | 1 | Gentium (Italy) | Digestive diseases - Liver diseases - Transplantation |
| 2013-11-12 | Hepastem® | Crigler-Najjar syndrome urea cycle disorders |
1-2 | Promethera Biosciences (Belgium) | Rare diseases - Genetic diseases - Metabolic diseases - Liver diseases - |
| 2013-11-12 | Xtandi® (enzalutamide) | prostate cancer | 4 | Medivation (USA - CA) Astellas (Japan) | Cancer - Oncology |
| 2013-11-11 | cannabinoids in combination with temozolomide | glioblastoma multiforme (GBM) | 1b-2a | GW Pharmaceuticals (UK) | Cancer - Oncology |
| 2013-11-09 | MK-7243 (Grazax® in Europe - grass allergy immunotherapy tablet) | grass pollen allergy |
3 | Merck&Co (USA) ALK Abello (Denmark) | Respiratory diseases - Allergic diseases |
| 2013-11-08 | tuberculosis vaccine SSI H56: IC31/AERAS-456 | tuberculosis |
1-2a | Statens Serum Institut (Denmark) Aeras (USA) | Infectious diseases |
| 2013-11-08 | Ruconest® (recombinant human C1 esterase inhibitor, or rhC1INH - conestat alfa) | acute attacks of angioedema in patients with Hereditary Angioedema (HAE) | 3 | Pharming Group (The Netherlands) Santarus (USA) | Genetic diseases - Rare diseases |
| 2013-11-07 | Duchenne muscular dystrophy (DMD) |
observational | Prosensa (The Netherlands) GSK (UK) | Genetic diseases - Neuromuscular diseases - Rare diseases | |
| 2013-11-05 | SOBI002 | 1 | Swedish Orphan Biovitrum (Sobi) (Sweden) | ||
| 2013-11-05 | Vyvanse® (lisdexamfetamine dimesylate) | binge eating disorder |
3 | Shire (UK-USA) | CNS diseases - Mental diseases |
| 2013-11-04 | VSN16R | multiple sclerosis | 1 | Canbex Therapeutics (UK) | Autoimmune diseases - Neurodegenerative diseases |
| 2013-11-04 | ALF-5755 (recombinant protein of the human protein HIP/PAP) | acute liver failure AIH- and HBV- related acute-on-chronic liver diseases |
2 | Alfact Innovation (France) | Hepatic diseases - Liver diseases |
| 2013-11-04 | vaccine against RSV | AIMM Therapeutics (The Netherlands) | Infectious diseases | ||
| 2013-11-04 | simeprevir (TMC435) and sofosbuvir (GS7977) | hepatitis C |
2 | Medivir (Sweden) Janssen Pharmaceutical (J&J - USA) | Infectious diseases |
| 2013-11-02 | combination of faldaprevir, deleobuvir and PPI-668 | hepatitis C |
2 | Boehringer Ingelheim (Germany) Presidio Pharmaceuticals (USA) | Infectious diseases |
| 2013-11-02 | combination of faldaprevir, pegylated interferon and ribavirin | hepatitis C |
3 | Boehringer Ingelheim (Germany) | Infectious diseases |
| 2013-11-02 | PREOB® | non-union fractures |
2b-3 | Bone Therapeutics (Belgium) | Bone diseases - Regenerative medicine |
